[go: up one dir, main page]

CO2022010592A2 - Métodos de tratamiento de la esplenomegalia - Google Patents

Métodos de tratamiento de la esplenomegalia

Info

Publication number
CO2022010592A2
CO2022010592A2 CONC2022/0010592A CO2022010592A CO2022010592A2 CO 2022010592 A2 CO2022010592 A2 CO 2022010592A2 CO 2022010592 A CO2022010592 A CO 2022010592A CO 2022010592 A2 CO2022010592 A2 CO 2022010592A2
Authority
CO
Colombia
Prior art keywords
splenomegaly
methods
treatment
therapeutic methods
treating
Prior art date
Application number
CONC2022/0010592A
Other languages
English (en)
Inventor
Wayne Philip Rothbaum
Original Assignee
Telios Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telios Pharma Inc filed Critical Telios Pharma Inc
Publication of CO2022010592A2 publication Critical patent/CO2022010592A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Solid Wastes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se describen métodos terapéuticos y composiciones farmacéuticas para tratar la esplenomegalia en un sujeto humano. En ciertas realizaciones, la invención incluye métodos terapéuticos para tratar la esplenomegalia usando un inhibidor de BTK.
CONC2022/0010592A 2020-01-08 2022-07-28 Métodos de tratamiento de la esplenomegalia CO2022010592A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062958632P 2020-01-08 2020-01-08
PCT/US2021/012696 WO2021142257A1 (en) 2020-01-08 2021-01-08 Methods of treating splenomegaly

Publications (1)

Publication Number Publication Date
CO2022010592A2 true CO2022010592A2 (es) 2022-10-31

Family

ID=76788747

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0010592A CO2022010592A2 (es) 2020-01-08 2022-07-28 Métodos de tratamiento de la esplenomegalia

Country Status (15)

Country Link
EP (2) EP4000624A1 (es)
JP (1) JP2023509968A (es)
KR (1) KR20220130151A (es)
CN (1) CN114423457A (es)
AU (1) AU2021205484A1 (es)
BR (1) BR112022013646A2 (es)
CA (1) CA3164063A1 (es)
CO (1) CO2022010592A2 (es)
CR (1) CR20220374A (es)
IL (1) IL294582A (es)
JO (1) JOP20220168A1 (es)
MA (2) MA63848B1 (es)
MX (1) MX2022008490A (es)
TN (1) TN2022000185A1 (es)
WO (1) WO2021142257A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240024314A1 (en) 2020-01-08 2024-01-25 Telios Pharma, Inc. Methods of Treating Splenomegaly
MA63848B1 (fr) * 2020-01-08 2024-10-31 Telios Pharma, Inc. Méthodes de traitement d'une splénomégalie
WO2022266285A1 (en) * 2021-06-16 2022-12-22 Telios Pharma Inc. Treatment of symptoms associated with myeloproliferative neoplasms
WO2023071973A1 (en) * 2021-10-26 2023-05-04 Shenzhen Targetrx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase
EP4577215A1 (en) * 2022-08-25 2025-07-02 BeiGene Switzerland GmbH Solid forms comprising (s) -7- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyrimidine-3-carboxamide, and oxalic acid, compositions and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
JP2016537433A (ja) * 2013-11-26 2016-12-01 ギリアード サイエンシーズ， インコーポレイテッド 骨髄増殖性障害を処置するための治療
RS62713B1 (sr) * 2014-08-11 2022-01-31 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora
US9708348B2 (en) * 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
BR112020025881A2 (pt) * 2018-06-19 2021-03-23 Merck Patent Gmbh formas cristalinas de 1-(4-{[6-amino-5-(4-fenóxi-fenil)-pirimidin-4-ilamino]-metil}-4-fluoro-piperidin-1-il)-propenona, formas de sal do mesmo e processos para obter as mesmas
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
MA63848B1 (fr) * 2020-01-08 2024-10-31 Telios Pharma, Inc. Méthodes de traitement d'une splénomégalie

Also Published As

Publication number Publication date
CN114423457A (zh) 2022-04-29
JP2023509968A (ja) 2023-03-10
CR20220374A (es) 2023-01-25
EP4000624A1 (en) 2022-05-25
MA57226A1 (fr) 2023-02-28
IL294582A (en) 2022-09-01
EP3980069A1 (en) 2022-04-13
KR20220130151A (ko) 2022-09-26
MA57226B1 (fr) 2023-06-28
BR112022013646A2 (pt) 2022-10-04
JOP20220168A1 (ar) 2023-01-30
MA63848B1 (fr) 2024-10-31
CA3164063A1 (en) 2021-07-15
EP3980069A4 (en) 2022-08-17
TN2022000185A1 (en) 2024-04-01
MA63848A1 (fr) 2024-04-30
MX2022008490A (es) 2022-10-13
AU2021205484A1 (en) 2022-08-18
WO2021142257A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
CO2022010592A2 (es) Métodos de tratamiento de la esplenomegalia
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
EA202091846A1 (ru) Соединения с активностью, индуцирующей ферроптоз, и способы их применения
MX2020009773A (es) Terapia de combinacion.
CO2020014599A2 (es) Métodos para tratar cáncer
CY1124123T1 (el) Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MX2023009685A (es) Inhibidores de tyk2 y sus usos.
CL2020002465A1 (es) Método de tratamiento de enfermedad fibrótica
CR20220071A (es) Composiciones farmacéuticas y métodos para tratar o prevenir la atrofia muscular espinal
EP4008718A4 (en) HETEROARYLAMIDOPYRIDINOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS AN ACTIVE PRINCIPLE FOR PREVENTING OR TREATING AN AUTOIMMUNE DISEASE
MX393452B (es) Tratamiento de los trastornos depresivos.
ECSP17019893A (es) Tratamientos médicos a base de anamorelina
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
MX2023009723A (es) Inhibidores de tyk2 y sus usos.
BR112022011228A2 (pt) Formulação farmacêutica líquida, artigo de fabricação, kit e método para tratar uma doença ou distúrbio em um indivíduo
JOP20210143A1 (ar) تركيبات وطرق لعلاج ومنع التصلب الجانبي الضموري
MX2021004396A (es) Metodos y composiciones para el tratamiento de la mucositis oral.
MX2021001549A (es) Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera.
MX2023013557A (es) Pauta posologica de sotorasib.
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.